medigraphic.com

2012, Number 2

<< Back Next >>

Rev Mex Anest 2012; 35 (2)

Sick and edematous astrocyte: Focus of attention in the pathophysiology of hepatic encephalopathy

Niño-de Mejía MC, Cohen MD, Paredes SP, Cuervo SJA

Language: Spanish
References: 28
Page: 115-121
PDF size: 81.34 Kb.


ABSTRACT

Hepatic encephalopathy is a neuropsychiatric syndrome that occurs in patients with acute and chronic liver failure. It has a very high incidence among cirrhotic patients, increase of circulating toxins reach the brain and cause multiple structural and functional abnormalities. The clinical manifestations and pathophysiology have been studied in detail. The role of the astrocyte in the onset of this clinical syndrome has been established, and it is now clear that there are multiple derangements in brain metabolism that account for cellular insult caused by liver failure. This paper offers a summary of the role of the astrocyte in preserving brain homeostasis, and how its structure and function are altered in hepatic encephalopathy, it provides a physiologic explanation to the clinical manifestations of this disease.


REFERENCES

  1. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295-2304.

  2. Yasemen E, Byrne W. Hepatic encephalopathy. Emerg Med Clin N Am 2009;27:401–414.

  3. Munoz SJ. Hepatic encephalopathy. Med Clin N Am 2008;92:795-812.

  4. Ference P, Lockwood A, Mullen KK, et al. Hepatic encephalopathy definition, nomenclature, diagnosis, and qualification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21.

  5. Córdoba CJ. La encefalopatía hepática hoy: cómo la incertidumbre mantiene algunas inercias clínicas. MedClin (Barc). 2009;132(11):425-427.

  6. Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:95–110.

  7. Riordan S, Williams R. Treatment of hepatic encephalopathy. NEJM 1997;337(7):473-479.

  8. Kapoor BS, Hunter DW, Greeno E, et al. Hepatic encephalopathy secondary to transtumoral portal venousshunting. Hepatogastroenterology 2003;50(49):4-7.

  9. Ieneke JC, Hartmann MD, Groeneweg M. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000;95:2029-2034.

  10. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M. Hepatic encephalopathy: A review, Annals of Hepatology 2003;2(3):122-130.

  11. Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006;55:98–104.

  12. Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 2005;38:696–9.

  13. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy, Gut 2008;57:1156-1165.

  14. Haussinger D, Kircheis G, Fischer FR, Schliess, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? JournaI of Hepatology 2000;32:1035-1038.

  15. Haussinger D, Schliess F. Astrocyte swelling and protein tyrosine nitration in hepatic encephalopathy. Neurochemistry International 2005;47:64-70.

  16. Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonaemic brain: Shedding new light on the pathophysiology of the brain damage in hyperammonaemia; J Inherit Metab Dis 2008;31:492-502.

  17. Felipo V. Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy; World J Gastroenterol 2006;12(48):7737-7743.

  18. Detry O, De Roover A, Honoré P, Meurisse M. Brain edema and intracranial hypertension in fulminant hepatic failure: Pathophysiology and management. World J Gastroenterol 2006;12(46):7405-7412.

  19. Hertz L, Zielke HR. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends in Neurosciences 2004;27(12):735-43.

  20. Blei AT. Brain edema in acute liver failure. Crit Care CIin 2008;24:99-114.

  21. Rama Rao KV, Norenberg MD. Aquaporin-4 in hepatic encephalopathy. Metab Brain Dis 2007;22:265-275.

  22. Morgan MY, Blei A, Grüngreiff K, Jalan R, Kircheis G, Marchesini G, Riggio O, Weissenbom K. The treatment of hepatic encephalopathy. Metab Brain Dis 2007;22:389-405.

  23. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549–59.

  24. Williams R, Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment on the hepatic encephalopathy: antimicrobial activity, efficacy, safety. Rev Gastroenterol Disord 2005;5(Suppl 1):S10–8.

  25. Leevy C, Phillips J. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737–41.

  26. Erceg S, Monfort P, Hernández-Viadel M, Llansola M, Montoliu C, Felipo V. Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain. Brain Res 2005;1036(1-2):115-21.

  27. Ferenci P. Treatment options for hepatic encephalopathy: a review. Semin Liver Dis 2007;27(Suppl 2):10-7.

  28. Canales JJ, Elayadi A, Errami M, Llansola M, Cauli O, Felipo V. Chronic hyperammonemia alters motor and neurochemical responses to activation of group I metabotropic glutamate receptors in the nucleus accumbens in rats in vivo. Neurobiol Dis 2003;14(3):380-90.




2020     |     www.medigraphic.com